{"id":"W3042207082","doi":"10.1136/annrheumdis-2020-eular.4736","title":"FRI0340 COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"AbbVie Canada; AbbVie; Celgene; Gilead Sciences; Galápagos; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Adalimumab; Secukinumab; Etanercept; Psoriasis; Psoriatic arthritis; Ustekinumab; Plaque psoriasis; Internal medicine; Psoriasis Area and Severity Index; Clinical endpoint; Dosing; Dermatology; Clinical trial; Gastroenterology; Rheumatoid arthritis","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003023879,0.001720238,0.004604038,0.0004239251,0.0003086478,0.001211147,0.0009281354,0.001411306,0.003945186],"category_scores_gemma":[0.001676357,0.0006133406,0.004567822,0.0004390803,0.0006875775,0.001059397,0.0006114431,0.002314877,0.0007377059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006578724,"about_ca_system_score_gemma":0.0005886867,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001274765,"about_ca_topic_score_gemma":0.00199312,"domain_scores_codex":[0.9986286,0.0006831523,0.0001166459,0.0002436147,0.0001402291,0.0001877886],"domain_scores_gemma":[0.9984838,0.0004811654,0.000410977,0.0002182066,0.00008293681,0.0003227956],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9729084,0.002451407,0.001816143,0.0005419346,0.004398848,0.00003791058,0.00004360885,0.000527095,0.003351663,0.00005601202,0.0003609663,0.01350599],"study_design_scores_gemma":[0.6438954,0.2662712,0.07283503,0.000193057,0.01076064,0.0001785675,0.0001485913,0.001984875,0.001858408,0.0002622275,0.001497882,0.0001141378],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919142,0.006018857,0.0001759235,0.0001505203,0.0001227643,0.0001367076,0.0006664008,0.00004540767,0.0007691685],"genre_scores_gemma":[0.9955824,0.001480822,0.000309397,0.0002282915,0.0002023969,0.0001975271,0.0007127898,0.00001913051,0.001267245],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004604038,"threshold_uncertainty_score":0.01599199,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09139180522912485,"score_gpt":0.3222439612649051,"score_spread":0.2308521560357803,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}